060  Calcitonin gene-related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. Issue 6 (27th May 2022)

• Record Type: Journal Article
• Authors: Yiangou, Andreas; Mitchell, James; Vijay, Vivek; Grech, Olivia; Bilton, Edward; Lavery, Gareth; Fisher, Claire; Edwards, Julie; Mollan, Susan; Sinclair, Alexandra
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 93:Issue 6(2022)
• Page Start: A119
• Page End: A119
• Publication Date: 2022-05-27
• Subjects: Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2022-ABN.385
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Background: Headache is the dominant factor for quality of life related disability in idiopathic intracranial hypertension (IIH) and typically has migraine-like characteristics. There are currently no evidence-based therapeutics for headache in IIH, and consequently this is an important unmet clinical need. Case series: We report a series of seven patients in whom headaches were the presenting feature of IIH the headaches had migraine-like characteristics, as is typical in many IIH patients. Papilloedema settled (ocular remission) but headaches continued. These headaches responded markedly to erenumab, a monoclonal antibody targeted against the calcitonin gene related peptide (CGRP) receptor. Of note, there was a recurrence of raised ICP, as evidenced by a return of the papilloedema, however the headaches did not recur whilst treated with erenumab. Conclusions: Those with prior IIH who have their headaches successfully treated with CGRP therapy, should remain under close ocular surveillance (particularly when weight gain is evident) as papilloedema can re-occur in the absence of headache. These cases may suggest that CGRP could be a mechanistic driver for headache in patients with active IIH. [e-mail]|NIHR Bursary 55